Nektar Therapeutics (NKTR)

NasdaqCM • Currently down 0.63 (-0.90%) in today's trading session

1 member of Congress has disclosed 4 trades in Nektar Therapeutics (NKTR) via STOCK Act filings. The most recent disclosure was a sale by Josh Gottheimer on 21 June 2018. Aggregate disclosed activity totals roughly $16K in purchases and $16K in sales (midpoint estimates from bracketed disclosure amounts).

Nektar Therapeutics is currently trading at $68.69, positioned at 54% of its 52-week range ($21.02 – $109.00).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Copy PortfolioClaim Free Asset
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$68.69
24h Change
-0.63 (-0.90%)
52 Week Range
$21.02—$109.00
View on NASDAQ

Nektar Therapeutics Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for NKTR

Select to highlight on chart
0 transactions
Compliance: 0%
No data

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$1.34B

Volume

261.88K

Beta

1.14

P/E Ratio

-8.17

Fundamentals

EPS

$-8.40

Div. Yield

—

Open

$69.28

Day Range

$67.71 — $69.95

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Howard W. Robin
IPO Date
1994-05-03
Website
www.nektar.com

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2...

Earnings

Next Report

Q2 2026

6 Aug

EPS Est.

$-1.94

Rev. Est.

$10.4M

Days Until

14

Recent Quarters

Q1 20267 May
EPS$-1.82
Miss 15.0%
Q4 202512 Mar
EPS$-1.78
Beat 35.5%
Q3 20256 Nov
EPS$-1.85
Beat 35.1%
Q2 20257 Aug
EPS$-2.95
Beat 5.8%
Q1 20258 May
EPS$-3.30
Miss 22.2%
Q4 202412 Mar
EPS$-2.25
Miss 15.4%
Q3 20247 Nov
EPS$-0.18
Beat 21.7%
Q2 20248 Aug
EPS$-0.25
Miss 19.1%
Q1 20249 May
EPS$-0.18
Beat 14.3%
Q4 20234 Mar
EPS$-0.22
Miss 10.0%
Q3 20237 Nov
EPS$-0.19
Miss 5.6%
Q2 20238 Aug
EPS$-0.27
Beat 10.0%
Q1 20239 May
EPS$-0.25
Beat 3.9%
Q4 202228 Feb
EPS$-0.32
Beat 28.9%
Q3 20223 Nov
EPS$-0.24
Beat 48.9%
Q2 20224 Aug
EPS$-0.85
Beat 15.8%
Q1 20225 May
EPS$-0.49
Beat 31.9%
Q4 202128 Feb
EPS$-0.79
Beat 2.5%
Q3 20214 Nov
EPS$-0.70
Beat 12.5%
Q2 20215 Aug
EPS$-0.69
Beat 4.2%
Q1 20216 May
EPS$-0.68
Beat 5.6%
Q4 202025 Feb
EPS$-0.65
Beat 9.7%
Q3 20205 Nov
EPS$-0.61
Beat 23.8%
Q2 20206 Aug
EPS$-0.45
Beat 34.8%
Q1 20207 May
EPS$-0.53
Beat 34.6%
Q4 201927 Feb
EPS$-0.64
Beat 7.3%
Q3 20196 Nov
EPS$-0.56
Beat 23.3%
Q2 20198 Aug
EPS$-0.63
Beat 21.3%
Q1 20198 May
EPS$-0.68
Beat 4.2%
Q4 201828 Feb
EPS$-0.57
Beat 18.6%
Q3 20187 Nov
EPS$-0.56
Beat 12.5%
Q2 20188 Aug
EPS$5.33
Beat 2.1%
Q1 201810 May
EPS$-0.60
Miss 15.4%
Q4 20171 Mar
EPS$-0.14
Beat 63.2%
Q3 20177 Nov
EPS$0.37
Beat 105.6%
Q2 20178 Aug
EPS$-0.39
Miss 11.4%
Q1 20179 May
EPS$-0.42
Miss 5.0%
Q4 20161 Mar
EPS$-0.28
Miss 7.7%
Q3 20163 Nov
EPS$-0.32
Beat 5.9%
Q2 20163 Aug
EPS$-0.36
Miss 12.5%
Q1 20163 May
EPS$-0.14
Beat 30.0%
Q4 20151 Mar
EPS$-0.40
Beat 9.1%
Q3 20155 Nov
EPS$-0.06
Beat 80.0%
Q2 20155 Aug
EPS$-0.40
Miss 48.1%
Q1 201530 Apr
EPS$0.25
Beat 162.5%
Q4 201424 Feb
EPS$-0.35
Beat 5.4%
Q3 20146 Nov
EPS$0.53
Beat 35.9%
Q2 201431 Jul
EPS$-0.26
Beat 31.6%
Q1 20147 May
EPS$-0.37
Miss 5.7%
Q4 201326 Feb
EPS$-0.41
Miss 156.3%
Q3 20137 Nov
EPS$-0.14
Beat 26.3%
Q2 20138 Aug
EPS$-0.37
Beat 15.9%
Q1 20139 May
EPS$-0.48
Miss 17.1%
Q4 201228 Feb
EPS$-0.46
Miss 2.2%
Q3 201213 Nov
EPS$-0.38
Beat 2.6%
Q2 20129 Aug
EPS$-0.30
Beat 11.8%
Q1 20122 May
EPS$-0.34
Miss 3.0%
Q4 201129 Feb
EPS$-0.33
Beat 31.3%
Q3 20112 Nov
EPS$-0.21
Beat 43.2%
Q2 20114 Aug
EPS$-0.32
Beat 3.0%
Q1 201127 Apr
EPS$-0.33
Miss 22.2%
Q4 20101 Mar
EPS$-0.11
Beat 31.3%
Q3 20104 Nov
EPS$-0.09
Miss 80.0%
Q2 201028 Jul
EPS$-0.01
Beat 93.1%
Q1 20105 May
EPS$-0.07
Beat 22.2%
Q4 20092 Mar
EPS$-0.08
Miss 592.0%
Q3 20094 Nov
EPS$-0.33
Beat 13.2%
Q2 20094 Aug
EPS$-0.35
Beat 14.6%
Q1 20096 May
EPS$-0.34
Beat 17.1%
Q4 200824 Feb
EPS$-0.45
Miss 45.2%
Q3 20086 Nov
EPS$-0.40
Miss 37.9%
Q2 20086 Aug
EPS$-0.36
Miss 16.1%
Q1 20087 May
EPS$-0.44
Miss 76.0%
Q4 200727 Feb
EPS$-0.11
Beat 52.2%
Q3 20077 Nov
EPS$-0.20
Beat 33.3%
Q2 20078 Aug
EPS$-0.30
Beat 0.0%
Q1 20079 May
EPS$-0.28
Beat 17.6%
Q4 200628 Feb
EPS$-0.37
Beat 5.1%
Q3 20062 Nov
EPS$-0.19
Beat 48.6%
Q2 20063 Aug
EPS$-0.34
Beat 8.1%
Q1 200610 May
EPS$-0.33
Beat 15.4%
Q4 200528 Feb
EPS$-0.40
Miss 5.3%
Q3 20053 Nov
EPS$-0.28
Beat 24.3%
Q2 20054 Aug
EPS$-0.32
Beat 5.9%
Q1 20059 May
EPS$-0.31
Miss 6.9%
Q4 20041 Mar
EPS$-0.23
Beat 14.8%
Q3 20043 Nov
EPS$-0.24
Beat 7.7%
Q2 20042 Aug
EPS$-0.27
Beat 3.6%
Q1 20045 May
EPS$-0.29
Beat 25.6%
Q4 20032 Feb
EPS$-0.38
Beat 20.8%
Q3 20035 Nov
EPS$-0.31
Beat 40.4%
Q2 20036 Aug
EPS$-0.23
Beat 50.0%
Q1 200322 Apr
EPS$-0.36
Beat 16.3%
Q4 200228 Jan
EPS$-0.51
Beat 1.9%
Q3 200222 Oct
EPS$-0.48
Beat 4.0%
Q2 200223 Jul
EPS$-0.44
Beat 4.3%
Q1 20022 May
EPS$-0.45
Miss 2.3%
Q4 200123 Jan
EPS$-0.37
Beat 0.0%
Q3 200124 Oct
EPS$-0.33
Beat 5.7%
Q2 20018 Aug
EPS$-0.34
Beat 5.6%
Q1 20011 May
EPS$-0.30
Beat 11.8%
Q4 200024 Jan
EPS$-0.31
Beat 6.1%
Q3 200023 Oct
EPS$-0.29
Miss 7.4%
Q2 200019 Jul
EPS$-0.28
Beat 3.5%
Q1 200019 Apr
EPS$-0.28
Beat 3.5%
Q4 199926 Jan
EPS$-0.30
Miss 3.5%
Q3 199925 Oct
EPS$-0.20
Miss 5.3%
Q2 199922 Jul
EPS$-0.17
Beat 0.0%
Q1 199921 Apr
EPS$-0.15
Beat 6.3%
Q4 199826 Jan
EPS$-0.19
Beat 0.0%
Q3 199822 Oct
EPS$-0.16
Beat 0.0%
Q2 199822 Jul
EPS$-0.09
Beat 35.7%
Q1 199821 Apr
EPS$-0.13
Beat 0.0%
Q4 199722 Jan
EPS$-0.10
Beat 33.3%
Q3 19976 Oct
EPS$-0.09
Beat 40.0%
Q2 199724 Jul
EPS$-0.08
Beat 33.3%
Q1 199724 Apr
EPS$-0.08
Beat 38.5%
Q4 199631 Jan
EPS$-0.14
Beat 12.5%
Q3 199622 Oct
EPS$-0.10
Beat 33.3%
Q2 199624 Jul
EPS$-0.11
Beat 15.4%
Q1 199617 Apr
EPS$-0.09
Beat 30.8%
Q4 199524 Jan
EPS$-0.11
Beat 38.9%
Q3 199524 Oct
EPS$-0.08
Beat 42.9%
Q2 199520 Jul
EPS$-0.08
Beat 38.5%
Q1 199520 Apr
EPS$-0.12
Beat 0.0%
Q4 199426 Jan
EPS$-0.13
Miss 8.3%
Q3 199424 Oct
EPS$-0.05
Beat 61.5%
Q2 199427 Jul
EPS$-0.08
Beat 27.3%
Q1 199430 Jun
EPS$-0.40

No dividend data available for this stock.

Stock Splits

Split History

9 Jun 2025Reverse Split
Ratio1:15
23 Aug 2000Stock Split
Ratio2:1

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

MSFT

Microsoft Corporation

42
$381.04-9.30 (-2.38%)
Technology
Held by same politician
$24M in total holdings
1 politician
View Stock

VOO

Vanguard S&P 500 ETF

22
$678.12-8.91 (-1.30%)
Financial Services
Held by same politician
Significant holdings value
1 politician
View Stock

AAPL

Apple Inc.

20
$321.04-4.85 (-1.49%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

Frequently Asked Questions about NKTR

Which members of Congress have traded NKTR?
1 member of Congress has disclosed 4 trade in Nektar Therapeutics (NKTR) under the STOCK Act: Josh Gottheimer.
When was NKTR most recently disclosed by Congress?
The most recent NKTR disclosure was a sale by Josh Gottheimer on 21 June 2018.
What is the total disclosed congressional trading volume for NKTR?
Members of Congress have disclosed approximately $16K in NKTR purchases and $16K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in NKTR?
This NKTR page updates as soon as new STOCK Act disclosures are filed for Nektar Therapeutics. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
Follow on XJoin our Discord
PoliticiansBillsPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.